ArticleInternational journal of molecular sciences2023

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.

Ixchel Lima-Posada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.